{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:08:29Z","timestamp":1793405309586,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clineuro.2026.109478","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:03:06Z","timestamp":1779084186000},"page":"109478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1\u2013associated plexiform neurofibromas: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"268","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3637-5033","authenticated-orcid":false,"given":"Sai","family":"Sanikommu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro N.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidya","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryLourdes","family":"Andreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo J.","family":"Komotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.clineuro.2026.109478_bib2","article-title":"Neurofibromatosis type 1","volume":"3","author":"Gutmann","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"11","key":"10.1016\/j.clineuro.2026.109478_bib3","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","article-title":"Management of neurofibromatosis type 1-associated plexiform neurofibromas","volume":"24","author":"Fisher","year":"2022","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W","article-title":"Plexiform neurofibromas","volume":"89","author":"Korf","year":"1999","journal-title":"Am. J. Med Genet"},{"key":"10.1016\/j.clineuro.2026.109478_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"Nguyen","year":"2012","journal-title":"Orphanet J. Rare Dis."},{"issue":"9","key":"10.1016\/j.clineuro.2026.109478_bib6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1002\/ajmg.a.37123","article-title":"Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life","volume":"167a","author":"Wolters","year":"2015","journal-title":"Am. J. Med Genet A"},{"issue":"26","key":"10.1016\/j.clineuro.2026.109478_bib7","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Dombi","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"15","key":"10.1016\/j.clineuro.2026.109478_bib8","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"21 1","key":"10.1016\/j.clineuro.2026.109478_bib9","first-page":"S6","article-title":"Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials","volume":"81","author":"Wolters","year":"2013","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.clineuro.2026.109478_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-015-1725-1","article-title":"Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature","volume":"122","author":"Vranceanu","year":"2015","journal-title":"J. Neurooncol"},{"issue":"5","key":"10.1016\/j.clineuro.2026.109478_bib11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor","volume":"15","author":"Ratner","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.clineuro.2026.109478_bib12","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.clineuro.2026.109478_bib13","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","article-title":"Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity","volume":"24","author":"Gross","year":"2022","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial","volume":"31","author":"Gross","year":"2025","journal-title":"Nat. Med"},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib15","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12916-023-02927-2","article-title":"Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas","volume":"21","author":"Hu","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.78010","article-title":"Trametinib in adults with neurofibromatosis type 1-related symptomatic plexiform neurofibromas","volume":"99","author":"Noordhoek","year":"2026","journal-title":"Ann. Neurol."},{"issue":"10496","key":"10.1016\/j.clineuro.2026.109478_bib17","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"Chen","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clineuro.2026.109478_bib18","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase iib trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.clineuro.2026.109478_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jpain.2007.09.005","article-title":"Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations","volume":"9","author":"Dworkin","year":"2008","journal-title":"J. Pain."},{"issue":"2","key":"10.1016\/j.clineuro.2026.109478_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.clineuro.2026.109478_bib21","series-title":"Cochrane handbook for systematic reviews of interventions","author":"Higgins","year":"2019"},{"key":"10.1016\/j.clineuro.2026.109478_bib22","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.clineuro.2026.109478_bib23","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"Gross","year":"2023","journal-title":"Neuro Oncol."},{"issue":"4","key":"10.1016\/j.clineuro.2026.109478_bib24","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1007\/s11912-009-0045-z","article-title":"Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"11","author":"Widemann","year":"2009","journal-title":"Curr. Oncol. Rep."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","article-title":"MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors","volume":"123","author":"Jessen","year":"2013","journal-title":"J. Clin. Invest"},{"issue":"7","key":"10.1016\/j.clineuro.2026.109478_bib26","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: a neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"Weiss","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109478_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11523-022-00888-9","article-title":"Cobimetinib in pediatric and young adult patients with relapsed or refractory solid tumors (iMATRIX-cobi): a multicenter, phase I\/II study","volume":"17","author":"Trippett","year":"2022","journal-title":"Target Oncol."},{"key":"10.1016\/j.clineuro.2026.109478_bib28","article-title":"Efficacy and safety of tunlametinib in adults with inoperable neurofibromatosis type 1-associated plexiform neurofibromas: phase IIa trial and biomarker research","author":"Wang","year":"2026","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.clineuro.2026.109478_bib29","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/neuonc\/noae121","article-title":"Safety and efficacy of selumetinib in pediatric and adult patients with neurofibromatosis type 1 and plexiform neurofibroma","volume":"26","author":"Kim","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib30","article-title":"The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas","volume":"2","author":"Jackson","year":"2020","journal-title":"Neurooncol Adv."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib31","article-title":"A single-center case study series assessing the effect of selumetinib use in patients with neurofibromatosis-related plexiform neurofibromas","volume":"6","author":"Passos","year":"2024","journal-title":"Neurooncol Adv."},{"issue":"3","key":"10.1016\/j.clineuro.2026.109478_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11060-025-05197-5","article-title":"Real-world experience with selumetinib in children with neurofibromatosis type 1: a multicentric retrospective study","volume":"175","author":"Santoro","year":"2025","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.clineuro.2026.109478_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221144930","article-title":"Safety and efficacy of mek inhibitors in the treatment of plexiform neurofibromas: a retrospective study","volume":"30","author":"Cacchione","year":"2023","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.clineuro.2026.109478_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11060-020-03443-6","article-title":"Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience","volume":"147","author":"Esp\u00edrito Santo","year":"2020","journal-title":"J. Neurooncol"},{"issue":"8","key":"10.1016\/j.clineuro.2026.109478_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29633","article-title":"Selumetinib for symptomatic, inoperable plexiform neurofibromas in children with neurofibromatosis type 1: a national real-world case series","volume":"69","author":"Coltin","year":"2022","journal-title":"Pedia Blood Cancer"},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2025.103438","article-title":"The first year of treatment with selumetinib for NF1-related plexiform neurofibroma is medically challenging in real-life settings","volume":"153","author":"Boitez","year":"2025","journal-title":"Ann. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.clineuro.2026.109478_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.5114\/polp.2025.156337","article-title":"Therapy with selumetinib in children with neurofibromatosis type 1 in Poland \u2013 clinical experience of the first year of the national program","volume":"100","author":"Styczy\u0144ska","year":"2025","journal-title":"Pediatr. Pol."},{"issue":"1","key":"10.1016\/j.clineuro.2026.109478_bib38","article-title":"Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study","volume":"5","author":"Suenobu","year":"2023","journal-title":"Neurooncol Adv."},{"issue":"2","key":"10.1016\/j.clineuro.2026.109478_bib39","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11060-025-05419-w","article-title":"Patient-reported outcomes as prognostic indicators for overall survival and progression-free survival in brain tumor patients - a systematic review and meta-analysis of randomized clinical trials","volume":"176","author":"Sanikommu","year":"2026","journal-title":"J. Neurooncol"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726001708?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846726001708?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T02:24:18Z","timestamp":1786242258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846726001708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":39,"alternative-id":["S0303846726001708"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109478","relation":{},"ISSN":["0303-8467"],"issn-type":[{"value":"0303-8467","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1\u2013associated plexiform neurofibromas: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2026.109478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109478"}}